中国生化药物杂志2017,Issue(4) :401-403.DOI:10.3969/j.issn.1005-1678.2017.04.132

局部晚期乳腺癌给予多西他赛及阿霉素的临床效果研究

Clinical efficacy of locally advanced breast cancer treated with docetaxel and doxorubicin

吴国法 赵振华 张群伟 朱霞瑾
中国生化药物杂志2017,Issue(4) :401-403.DOI:10.3969/j.issn.1005-1678.2017.04.132

局部晚期乳腺癌给予多西他赛及阿霉素的临床效果研究

Clinical efficacy of locally advanced breast cancer treated with docetaxel and doxorubicin

吴国法 1赵振华 1张群伟 1朱霞瑾1
扫码查看

作者信息

  • 1. 浙江省海宁市人民医院,浙江 海宁 314400
  • 折叠

摘要

目的 评价多西他赛联合阿霉素在治疗局部晚期乳腺癌中的具体方法及其临床效果,并对其安全性进行评估.方法 回顾性分析浙江省海宁市人民医院2012年7月~2016年7月接受并治疗的72 例局部晚期乳腺癌患者的临床资料,参照随机双盲法将其分别划入对照组和实验组,每组36 例.对照组给予环磷酰胺、5-氟尿嘧啶及氨甲喋呤治疗,实验组则给予多西他赛联合阿霉素进行治疗,均以21 天为1 个周期,2 个周期用药完成后评估比较2 组患者的临床疗效、毒副反应及生活质量.结果 实验组患者的治疗总缓解率为75.0%,相较于对照组的41.7%明显更高( P< 0.05);两组患者的主要不良反应为胃肠道反应与骨髓抑制,且多为 0~ Ⅰ度,恶心呕吐、脱发、腹泻、疲乏、白细胞减少、血小板下降、心率失常、肝功能异常以及末梢静脉炎等毒副反应的发生率与对照组相比差异均无统计学意义;2组治疗前QOL评分差异无统计学意义,治疗后2组评分均有所增高,组间治疗前后对比差异有统计学意义( P< 0.05),相比下实验组的增高幅度明显更优( P< 0.05).结论 应用多西他赛联合阿霉素治疗局部晚期乳腺癌疗效确切,且毒副反应轻微均在患者可耐受范围,对促进患者康复、提升其生活质量具有十分积极的意义.

Abstract

Objective To evaluate the specific methods and clinical efficacy of docetaxel combined with doxorubicin in the treatment of locally advanced breast cancer and to evaluate its safety.MethodsThe clinical data of 72 pitients with locally advanced breast cancer who were treated in our hospital from July 2012 to July 2016 were retrospectively analyzed.According to the random double blind method,the patients were divided into the control group and the experimental group,with 36 cases in each group.The control group were treated with cyclophosphamide,5-fluorouracil and ammonia armor pterin methotrexate treatment,the experimental group were treated with docetaxel combined with adriamycin treatment,21 days for a cycle,withThe clinical curative effect,toxicity and quality of life were compared between the two groups of patients two cycles of treatment after the completion of the assessment.Results The total remission rate of the experimental group was 75.0%,which was significantly higher than that in control group 41.7%(P<0.05); the main adverse reactions were gastrointestinal reaction and bone marrow suppression,two groups of patients with 0-I,nausea and vomiting,hair loss,diarrhea,fatigue,white blood cell reduction,blood loss,blood loss,heart rate disorders,abnormal liver function and peripheral phlebitis.Two groups were compared.The two groups had no significant difference.Conclusion Docetaxel combined with adriamycin in the treatment of locally advanced breast cancer had definite and toxic and side reaction were slightly in patients can tolerance range,to promote the rehabilitation of patients,improve the quality of life has a very positive significance for popularization and application in the medical practice.

关键词

乳腺癌/多西他赛/阿霉素

Key words

breast cancer/docetaxel/adriamycin

引用本文复制引用

出版年

2017
中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
被引量4
参考文献量12
段落导航相关论文